For smaller late-stage biotech companies, commercialization has always involved a series of high-stakes choices: where to invest, how much infrastructure to build, when to expand internationally, and whether to partner or go it alone. The US Most Favored Nation (MFN) policy raises the stakes of each of these decisions. While much of the discussion around MFN has focused on the risk of US price compression, the implications extend far beyond lower US prices. MFN has the potential to rebalance global pricing logic, creating new pressures and opportunities across markets.
For smaller biotechs, the challenge is not simply pricing pressure. It is how to preserve asset value in a world where pricing, launch, and access decisions in one geography can increasingly shape outcomes elsewhere. As the US becomes more exposed to external pricing benchmarks, companies may need to rethink globalization strategies, launch sequencing, partnership models, evidence generation, and the trade-offs between price, access, and value preservation.
In this whitepaper, we explore how MFN is changing the commercialization equation for late-stage biotechs and why a more integrated, globally coordinated approach to pricing and market access is becoming essential. We examine the strategic implications for US and ex-US biotechs alike and outline the key considerations companies should address to build an MFN-ready commercialization strategy.
